The Influence of the MDR1 C3435T Polymorphism on Methotrexate Responsiveness in Rheumatoid Arthritis Patients
July 2020
in “
The Egyptian Journal of Hospital Medicine
”
TLDR The MDR1 C3435T polymorphism does not significantly affect methotrexate response in rheumatoid arthritis patients.
The study investigated the influence of the MDR1 C3435T polymorphism on methotrexate (MTX) responsiveness in 90 rheumatoid arthritis (RA) patients. The patients were categorized into MTX responders and non-responders based on their disease activity score (DAS28). The results showed no statistically significant difference in genotype or allele frequencies between the two groups. However, patients with the C allele were 1.65 times more likely to be non-responders compared to those with the T allele. Common adverse effects of MTX included gastrointestinal upset (31.1%) and hair loss (11.1%). The study concluded that there was no significant association between the MDR1 C3435T polymorphism and MTX responsiveness in the RA patients studied.